The purpose of this study was to determine whether the fluoroquinolone (FQ) minimum inhibitory concentration (MIC) for the causative agent Escherichia coli influences the clinical response of FQ treatment at 72 h in patients with community-acquired acute pyelonephritis (CA-APN). We prospectively collected the clinical data of women with CA-APN from 11 university hospitals from March 2010 to February 2012 as well as E. coli isolates from the urine or blood. In total, 78 patients included in this study received FQ during the initial 72 h, and the causative E. coli was detected. The clinical response at 72 h was significantly higher in patients with a levofloxacin MIC ≤ 16 mg/L than in those with an MIC > 16 mg/L (70.4% vs. 28.6%, p = 0.038). No difference was observed in clinical response at 72 h based on ciprofloxacin MIC. To summarize, FQ can be an effective treatment option for CA-APN when levofloxacin MIC against E. coli is ≤16 mg/L.

中文翻译：

---

当左氧氟沙星对致病性大肠杆菌的最小抑菌浓度≤16mg / L时，氟喹诺酮可作为急性肾盂肾炎的有效治疗选择

这项研究的目的是确定对于社区获得性急性肾盂肾炎（CA-APN）患者，致病菌大肠杆菌的氟喹诺酮（FQ）最低抑菌浓度（MIC）是否会影响FQ治疗在72小时的临床反应。我们前瞻性收集了2010年3月至2012年2月间11家大学医院的CA-APN妇女的临床数据，以及从尿液或血液中分离出的大肠杆菌。总共有78名患者被纳入本研究，在最初的72小时内接受了FQ，并检测到病原性大肠杆菌。左氧氟沙星MIC≤16 mg / L的患者在72 h时的临床反应显着高于MIC> 16 mg / L的患者（70.4％vs. 28.6％，p= 0.038）。基于环丙沙星MIC，在72 h的临床反应中未观察到差异。总而言之，当左氧氟沙星MIC对大肠杆菌的≤16 mg / L时，FQ可能是CA-APN的有效治疗选择。